Get the Stockscreener App
2.00
3.38%
-0.07
After Hours:
2.04
0.04
+2.00%
Genprex Inc stock is traded at $2.00, with a volume of 244.04K.
It is down -3.38% in the last 24 hours and up +2.04% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$2.07
Open:
$2.06
24h Volume:
244.04K
Relative Volume:
0.26
Market Cap:
$4.54M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.1708
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-6.10%
1M Performance:
+2.04%
6M Performance:
-82.57%
1Y Performance:
-88.06%
1-Day Range:
$1.96
$2.0923
1-Week Range:
$1.89
$2.14
52-Week Range:
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
2.00 | 4.70M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
GNPX Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Genprex (NASDAQ: GNPX) CMO has shares withheld to cover RSU taxes - Stock Titan
Genprex (GNPX) CEO reports 9,330-share tax-withholding disposition - Stock Titan
Should You Buy Genprex Inc (GNPX) Today? Analysis, Price Targets, and 2026 Outlook. - Intellectia AI
Congressional Trading Activity Insights - Intellectia AI
Genprex bags major patent wins in Japan & Europe for REQORSA cancer therapy - Indian Pharma Post
Congressman Who Bought Small-Cap Stocks In 2025 Is Back With New 2026 Pick: Here's What He's Buying - Benzinga
Genprex Advances Cancer Therapy Strategy with Key International Patents - AD HOC NEWS
Genprex receives Japanese and European patents for cancer therapy By Investing.com - Investing.com India
Genprex stock jumps on Japan, Europe patent approvals By Investing.com - Investing.com Nigeria
Genprex stock jumps on Japan, Europe patent approvals - Investing.com
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Genprex (GNPX) Gains Global Patent Approvals for Innovative Canc - GuruFocus
Genprex Secures Key Global Patents for REQORSA Therapy - TipRanks
Genprex receives Japanese and European patents for cancer therapy - Investing.com
Genprex secures Japan, EU patents for REQORSA combos, bolstering Acclaim-3 IP and trial - TradingView
New cancer patents support Genprex (NASDAQ: GNPX) Acclaim-3 trial - Stock Titan
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer - Barchart.com
Genprex Navigates a Pivotal Juncture Amid Clinical Progress and Financial Strain - AD HOC NEWS
Published on: 2026-02-21 03:40:37 - baoquankhu1.vn
Will Genprex Inc. benefit from green energy policiesChart Signals & Accurate Trade Setup Notifications - mfd.ru
How strong is Genprex Inc. (2DE0) stock earnings growth2025 Short Interest & Precise Swing Trade Entry Alerts - mfd.ru
Genprex receives patent approval in Australia for cancer therapy By Investing.com - Investing.com Canada
Genprex receives patent approval in Australia for cancer therapy - Investing.com Australia
Ayrton Capital-led group reports 9.72% Genprex (GNPX) stake via warrants - Stock Titan
Genprex Announces IP Australia's Intent to Grant Patent for Reqorsa® Gene Therapy in Combination with PD-L1 Antibodies to Treat Cancers - BioSpace
Genprex (GNPX) Gains Australian Patent Approval for Cancer Treat - GuruFocus
Genprex Gains Australian Patent Acceptance for REQORSA Therapy - TipRanks
Genprex Announces Ip Australia's Intent To Grant Patent For Reqorsa® Gene Therapy - TradingView
Genprex Patent Acceptance and Clinical Trial Expansion - TradingView
Genprex (NASDAQ: GNPX) advances REQORSA patent strategy and expands Acclaim-3 lung cancer trial - Stock Titan
Bull Run: Will Genprex Inc benefit from green energy policiesPortfolio Gains Report & Short-Term Swing Trade Alerts - baoquankhu1.vn
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Genprex Shares Seek Catalysts Amid Clinical Trial Focus - AD HOC NEWS
Institution Moves: What are the analyst revisions for Guess IncIs Genprex Inc stock a good investment in YEARExit Point & Short-Term Trading Alerts - baoquankhu1.vn
Aug PreEarnings: Will Genprex Inc outperform tech stocksShort Setup & Safe Entry Point Identification - baoquankhu1.vn
Aug Patterns: Whats the outlook for TMD Energy Limiteds sectorWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
Aug Spikes: How does Genprex Inc score in quality rankingsFed Meeting & High Accuracy Investment Signals - baoquankhu1.vn
Take Profit: Is Genprex Inc stock a defensive play in 20252025 Sector Review & Verified Stock Trade Ideas - Bộ Nội Vụ
Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail
MSN Money - MSN
Genprex Regains Nasdaq Compliance - TradingView — Track All Markets
Congressman who was top 2025 stock picker buys shares of $5M company you've never heard of - MSN
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Benzinga
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX) - Defense World
Will Genprex Inc. stock remain a Wall Street favorite2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Can Genprex Inc. stock beat market expectations this quarterShort Setup & Safe Entry Point Identification - ulpravda.ru
Can Genprex Inc. stock sustain market leadershipWeekly Trading Summary & AI Based Trade Execution Alerts - Улправда
PRN_FinancialWrapper | PR NewswireGenprex, Inc.Common Stock (Nasdaq:GNPX) Price Chart - FinancialContent
Why analysts upgrade Genprex Inc. stock2025 Market WrapUp & Risk Controlled Swing Alerts - ulpravda.ru
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):